Exelixis, Inc. (NASDAQ:EXEL) authorized repurchasing up to an additional $500 million of the company’s common stock before ...

Exelixis, Inc. ( NASDAQ:EXEL ) recently posted some strong earnings, and the market responded positively. We did ...

We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...

Exelixis reported increased revenue and earnings in Q4 2024, driven by strong cabozantinib sales, though competitive ...

Newly published detailed clinical trial data show why Exelixis abandoned a plan to seek an FDA approval for a combination of ...

Exelixis’ next-generation tyrosine kinase inhibitor zanzalintinib is being tested for colorectal cancer, renal cell carcinoma ...

Operator Good day, ladies and gentlemen, and welcome to the Exelixis fourth quarter and fiscal year 2024 financial results ...

Exelixis reported $515.2M in net product revenues in Q4'24, a 20% increase over net product revenues for Q4'23. See why I ...

Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in a fireside chat at the Citi 2025 ...

Exelixis (EXEL) announced final results from the phase 3 CheckMate -9ER pivotal trial evaluating Cabometyx in combination with Opdivo versus ...

(RTTNews) - Exelixis, Inc. (EXEL) Thursday announced that its Board of Directors has authorized an additional $500 million stock repurchase program, set to run through December 31. The company ...

“Exelixis delivered a strong fourth quarter of 2024, positioning us well to maximize success in 2025,” said Michael M. Morrissey, Ph.D., President and Chief Executive Officer, Exelixis.